1-3 of 3
Qiang He
Close
Sort by
Journal Articles

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Hui Wang, Qiang He, Rongrong Zhao, Linna Xie, Ji Ma, Cong Liu, Ke Lu, Haichen Wei, Dan Liu, Lijie Xing, Xiuzhi Deng, Zhongliang Sun, Xiaoxia Chu, Na Gao, Yuping Zhong, Yanhua Sun, Haiyan Zhang, Hao Zhang, Wenwei Xu, Zengjun Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 11962–11963.
https://doi.org/10.1182/blood-2022-162507
Published: 2022
Journal Articles

Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Qiang He, Linna Xie, Rongrong Zhao, Ji Ma, Hui Wang, Jie Li, Chuanli Zhao, Y. Lynn Wang, Zengjun Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 6614–6615.
https://doi.org/10.1182/blood-2022-168859
Published: 2022
Journal Articles

A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma

Ji Ma, Qiang He, Ke Lu, Liang Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3744–3745.
https://doi.org/10.1182/blood-2022-165720
Published: 2022